STOCK TITAN

[144] LifeStance Health Group, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

LifeStance Health Group, Inc. (LFST) filed a Form 144 notifying a proposed sale of 894,098 shares of Common Stock through Morgan Stanley & Co. LLC, with an aggregate market value of $4,837,070.18. The filing lists the approximate date of sale as 08/18/2025 and the securities exchange as NASDAQ.

The shares were acquired pre-IPO on 06/10/2021 from the issuer, with 5,130,460 shares originally acquired on that date. The filer reports no securities sold in the past three months and includes the required certification that no undisclosed material adverse information is known.

LifeStance Health Group, Inc. (LFST) ha presentato un modulo Form 144 per notificare la proposta vendita di 894.098 azioni ordinarie tramite Morgan Stanley & Co. LLC, per un controvalore complessivo di $4.837.070,18. Il deposito indica la data approssimativa della vendita come 18/08/2025 e la borsa di negoziazione come NASDAQ.

Le azioni erano state acquisite prima dell'IPO il 10/06/2021 dall'emittente, per un totale originario di 5.130.460 azioni acquistate in quella data. Il dichiarante riferisce di non aver venduto titoli negli ultimi tre mesi e include la certificazione richiesta che non esistono informazioni materiali avverse non divulgate.

LifeStance Health Group, Inc. (LFST) presentó un Formulario 144 notificando la propuesta de venta de 894.098 acciones ordinarias a través de Morgan Stanley & Co. LLC, por un valor de mercado agregado de $4.837.070,18. El expediente indica la fecha aproximada de venta como 18/08/2025 y la bolsa como NASDAQ.

Las acciones se adquirieron antes de la salida a bolsa el 10/06/2021 por parte del emisor, con 5.130.460 acciones originalmente obtenidas en esa fecha. El declarante informa que no se han vendido valores en los últimos tres meses e incluye la certificación requerida de que no conoce información material adversa no divulgada.

LifeStance Health Group, Inc. (LFST)는 Morgan Stanley & Co. LLC를 통해 보통주 894,098주를 매각할 예정임을 통지하는 Form 144를 제출했으며, 총 시가 가치는 $4,837,070.18입니다. 제출서에는 매각 예정일을 2025-08-18로, 거래소를 NASDAQ으로 기재했습니다.

해당 주식은 2021-06-10에 발행사로부터 IPO 이전에 취득되었으며, 당시 총 5,130,460주가 취득되었습니다. 제출자는 지난 3개월간 매도한 증권이 없음을 보고하고, 미공개의 중대한 불리한 정보가 없다는 필수 인증서를 포함했습니다.

LifeStance Health Group, Inc. (LFST) a déposé un formulaire 144 pour notifier la vente proposée de 894 098 actions ordinaires via Morgan Stanley & Co. LLC, pour une valeur marchande totale de 4 837 070,18 $. Le dépôt indique la date approximative de la vente au 18/08/2025 et la bourse comme NASDAQ.

Les actions ont été acquises avant l'introduction en bourse le 10/06/2021 auprès de l'émetteur, 5 130 460 actions ayant été initialement obtenues à cette date. Le déclarant signale n'avoir vendu aucun titre au cours des trois derniers mois et inclut la certification requise qu'aucune information défavorable importante non divulguée n'est connue.

LifeStance Health Group, Inc. (LFST) reichte ein Formular 144 ein, um einen geplanten Verkauf von 894.098 Stammaktien über Morgan Stanley & Co. LLC zu melden; der Gesamtmarktwert beträgt $4.837.070,18. In der Einreichung ist das ungefähre Verkaufsdatum mit 18.08.2025 und die Börse mit NASDAQ angegeben.

Die Aktien wurden vor dem Börsengang am 10.06.2021 vom Emittenten erworben; ursprünglich wurden an diesem Datum 5.130.460 Aktien erworben. Der Melder gibt an, in den letzten drei Monaten keine Wertpapiere verkauft zu haben, und fügt die erforderliche Bescheinigung bei, dass keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind.

Positive
  • Brokered sale disclosed: Sale will be executed through Morgan Stanley & Co. LLC, providing a clear execution channel.
  • No recent sales: The filer reports "Nothing to Report" for securities sold during the past three months, indicating no near-term prior disposals.
  • Acquisition details provided: The filing specifies the pre-IPO acquisition date (06/10/2021) and number of shares acquired (5,130,460), supporting transparency.
Negative
  • Insider sale announced: Proposed sale of 894,098 shares with aggregate value of $4,837,070.18, which may be viewed negatively by some investors.
  • Reduction of pre-IPO holdings: The filer originally acquired 5,130,460 shares pre-IPO and is selling a portion of that holding.

Insights

TL;DR Routine insider notice of a planned sale via a broker; not a mandatory disclosure of adverse events.

The filing documents a proposed Rule 144 sale of 894,098 shares executed through Morgan Stanley & Co. LLC with a stated market value of $4.84 million and a projected sale date of 08/18/2025. The shares originated from a pre-IPO acquisition on 06/10/2021 totaling 5,130,460 shares. The notice states no sales in the past three months, consistent with standard Rule 144 timing and reporting. For investors, this is a disclosure of insider selling activity rather than operational or financial performance information.

TL;DR Filing appears to follow Rule 144 disclosure requirements; includes broker and acquisition details and the required signer representation.

The form identifies the broker (Morgan Stanley & Co. LLC), the class of security, the number of shares to be sold, aggregate market value, and the date of acquisition (pre-IPO on 06/10/2021). It also confirms there were no sales in the prior three months and contains the seller's certification about material information. These elements align with routine compliance expectations for a Rule 144 notice. The filing does not include any additional operational or material governance disclosures.

LifeStance Health Group, Inc. (LFST) ha presentato un modulo Form 144 per notificare la proposta vendita di 894.098 azioni ordinarie tramite Morgan Stanley & Co. LLC, per un controvalore complessivo di $4.837.070,18. Il deposito indica la data approssimativa della vendita come 18/08/2025 e la borsa di negoziazione come NASDAQ.

Le azioni erano state acquisite prima dell'IPO il 10/06/2021 dall'emittente, per un totale originario di 5.130.460 azioni acquistate in quella data. Il dichiarante riferisce di non aver venduto titoli negli ultimi tre mesi e include la certificazione richiesta che non esistono informazioni materiali avverse non divulgate.

LifeStance Health Group, Inc. (LFST) presentó un Formulario 144 notificando la propuesta de venta de 894.098 acciones ordinarias a través de Morgan Stanley & Co. LLC, por un valor de mercado agregado de $4.837.070,18. El expediente indica la fecha aproximada de venta como 18/08/2025 y la bolsa como NASDAQ.

Las acciones se adquirieron antes de la salida a bolsa el 10/06/2021 por parte del emisor, con 5.130.460 acciones originalmente obtenidas en esa fecha. El declarante informa que no se han vendido valores en los últimos tres meses e incluye la certificación requerida de que no conoce información material adversa no divulgada.

LifeStance Health Group, Inc. (LFST)는 Morgan Stanley & Co. LLC를 통해 보통주 894,098주를 매각할 예정임을 통지하는 Form 144를 제출했으며, 총 시가 가치는 $4,837,070.18입니다. 제출서에는 매각 예정일을 2025-08-18로, 거래소를 NASDAQ으로 기재했습니다.

해당 주식은 2021-06-10에 발행사로부터 IPO 이전에 취득되었으며, 당시 총 5,130,460주가 취득되었습니다. 제출자는 지난 3개월간 매도한 증권이 없음을 보고하고, 미공개의 중대한 불리한 정보가 없다는 필수 인증서를 포함했습니다.

LifeStance Health Group, Inc. (LFST) a déposé un formulaire 144 pour notifier la vente proposée de 894 098 actions ordinaires via Morgan Stanley & Co. LLC, pour une valeur marchande totale de 4 837 070,18 $. Le dépôt indique la date approximative de la vente au 18/08/2025 et la bourse comme NASDAQ.

Les actions ont été acquises avant l'introduction en bourse le 10/06/2021 auprès de l'émetteur, 5 130 460 actions ayant été initialement obtenues à cette date. Le déclarant signale n'avoir vendu aucun titre au cours des trois derniers mois et inclut la certification requise qu'aucune information défavorable importante non divulguée n'est connue.

LifeStance Health Group, Inc. (LFST) reichte ein Formular 144 ein, um einen geplanten Verkauf von 894.098 Stammaktien über Morgan Stanley & Co. LLC zu melden; der Gesamtmarktwert beträgt $4.837.070,18. In der Einreichung ist das ungefähre Verkaufsdatum mit 18.08.2025 und die Börse mit NASDAQ angegeben.

Die Aktien wurden vor dem Börsengang am 10.06.2021 vom Emittenten erworben; ursprünglich wurden an diesem Datum 5.130.460 Aktien erworben. Der Melder gibt an, in den letzten drei Monaten keine Wertpapiere verkauft zu haben, und fügt die erforderliche Bescheinigung bei, dass keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does LifeStance Health Group (LFST) report in this Form 144?

The filer notifies a proposed Rule 144 sale of 894,098 common shares through Morgan Stanley & Co. LLC, with aggregate market value $4,837,070.18, and an approximate sale date of 08/18/2025.

When were the shares being sold originally acquired?

The filing states the shares were acquired on 06/10/2021 in pre-IPO transactions from the issuer, totaling 5,130,460 shares acquired on that date.

Has the filer sold any LFST securities in the past three months?

The Form 144 indicates "Nothing to Report" for securities sold during the past three months.

Through which broker will the LFST shares be sold?

The sale is to be handled by Morgan Stanley & Co. LLC, located at 1585 Broadway, New York, NY, as listed in the filing.

What exchange will the proposed LFST sale occur on?

The filing lists the NASDAQ as the securities exchange for the proposed sale.
Lifestance Health Group, Inc.

NASDAQ:LFST

LFST Rankings

LFST Latest News

LFST Latest SEC Filings

LFST Stock Data

2.12B
136.33M
8.24%
94.68%
1.91%
Medical Care Facilities
Services-health Services
Link
United States
SCOTTSDALE